About Tumor necrosis factor alpha-induced protein 8-like protein 3
Tumor necrosis factor alpha-induced protein 8-like protein 3 (TNFAIP8L3) is a protein
from Homo sapiens identified by UniProt accession
Q5GJ75, 292 residues long.
MolForge cross-references it against 0 known binders and
85 disease associations.
Target properties
| Protein name | Tumor necrosis factor alpha-induced protein 8-like protein 3 |
|---|
| UniProt accession | Q5GJ75 |
|---|
| Gene | TNFAIP8L3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 292 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (85)
Diseases linked to this target (Open Targets).
- keratoconus · score 0.32
- heel bone mineral density · score 0.32
- self reported educational attainment · score 0.28
- central corneal thickness · score 0.26
- appendicular lean mass · score 0.20
- cognitive function measurement · score 0.18
- creatinine measurement · score 0.17
- myeloid white cell count · score 0.15
- reticulocyte count · score 0.15
- vital capacity · score 0.15
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q5GJ75-F1 | alphafold | PREDICTED | 73.39 | — |
Amino-acid sequence (292 residues)
MGKPRQNPST LVSTLCEAEP KGKLWVNGYA GTQGTRDATL QTRLIPLSFH LQRGKGLAAP LSALSAPRLP ERPADGRVAV DAQPAARSMD SDSGEQSEGE PVTAAGPDVF SSKSLALQAQ KKILSKIASK TVANMLIDDT SSEIFDELYK VTKEHTHNKK EAHKIMKDLI KVAIKIGILY RNNQFSQEEL VIVEKFRKKL NQTAMTIVSF YEVEYTFDRN VLSNLLHECK DLVHELVQRH LTPRTHGRIN HVFNHFADVE FLSTLYSLDG DCRPNLKRIC EGINKLLDEK VL
Explore Tumor necrosis factor alpha-induced protein 8-like protein 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets